97323-00-7

Basic information

• Product Name: 5-[4-(6-butyryloxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
• Synonyms: 5-[4-(6-butyryloxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
• CAS NO: 97323-00-7
• Molecular Weight: 511.639
• Mol File: 97323-00-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 5-[4-(6-butyryloxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 5-[4-(6-butyryloxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione(97323-00-7)
• EPA Substance Registry System: 5-[4-(6-butyryloxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione(97323-00-7)

Safety Data

• Hazardous Substances Data: 97323-00-7(Hazardous Substances Data)

Upstream product

• 97322-68-4 Ethyl 3-<4-<(6-acetoxy-2,5,7,8-tetramethylchroman-2-yl)methoxy>phenyl>-2-chloropropionate 
• 118070-84-1 6-(Methoxymethoxy)-2,5,7,8-tetramethyl-2-<(4-nitrophenoxy)methyl>chroman 
• 118070-83-0 2,5,7,8-tetramethyl-6-acetoxy-2-(4-nitrophenyloxy)methylchroman 
• 107188-37-4 6-acetoxy-2-[(4-aminophenoxy)methyl]-2,5,7,8-tetramethylchromane 
• 107188-58-9 6-Hydroxy-2,5,7,8-tetramethyl-2-<(4-nitrophenoxy)methyl>chroman 
• 107188-55-6 2-hydroxymethyl-6-methoxymethoxy-2,5,7,8-tetramethylchroman 
• 79907-49-6 2-hydroxymethyl-2,5,7,8-tetramethyl-chroman-6-ol 
• 97322-87-7 Troglitazone 

Relevant articles and documents

Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation

A series of hindered phenols were investigated as hypolipidemic and/or hypoglycemic agents with ability to inhibit lipid peroxidation. 1,3-Benzoxathioles (9 and 22), phenoxypentanoic acid (34), phenoxypentanol (35a), phenoxynonanol (35b), phenylchloropropionic acid having a chromanyl group (25), and a thiazolidine compound (27) derived from 25, all having a hindered phenol group, were prepared and examined. Compound 27 showed the expected biological properties in vivo and in vitro without any liver weight increase. Biological activities of the analogous thiazolidine compounds, 43-58, were compared. Thus, roxy-2,5,7,8-tetramethylchroman-2-yl(methoxy]-benzyl]-2,4-thiazolidinedione (27) (CS-045) was found to have all our expected properties and was selected as a candidate for further development as a hypoglycemic and hypolipidemic agent.